REMI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
REMI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Remedent's EPS without NRI for the three months ended in Dec. 2020 was $0.01.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
For the Medical Instruments & Supplies subindustry, Remedent's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Remedent's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Remedent's 3-Year EPS without NRI Growth Rate falls into.
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
Remedent (OTCPK:REMI) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Thank you for viewing the detailed overview of Remedent's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Stuart Steinberg | 10 percent owner | 85 BELLEVUE AVENUE, RYE NY 10580 |
Marxe Austin W & Greenhouse David M | 10 percent owner | C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022 |
Gruber & Mcbaine Capital Management Llc | 10 percent owner | 234 VAN NESS, STE 5, SAN FRANCISCO CA 94133 |
Stephen Farley Ross | director, officer: CFO; Secretary | XAVIER DE COCKLAAN 42 DEURLE C9 9831 |
Fred Kolsteeg | director | XAVIER DE COCKLAAN 42 DEURLE C9 9831 |
Acker Philippe Van | director | C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 9831 DEURLE C9 9831 |
Robin List | other: Former Officer and Director | XAVIER DE COCKLAAN 42 DEURLE C9 9831 |
Roger Leddington | officer: Sr VP & Head of US Marketing | C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 DEURLE C9 9831 |
Guy Devreese | director, officer: Chairman of the Board | XAVIER DE COCKLAAN 42 DEURLE C9 9831 |
Judd Darrin Hoffman | officer: VP Worldwide Sales/Operations | 702A JUANITA AVENUE REDONDO BEACH CA 90277 |
Nv Lausha | 10 percent owner | C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 9831 DEURLE C9 9831 |
From GuruFocus
By Frank Lind Frank Lind • 05-26-2011
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.